Please login to the form below

Not currently logged in
Email:
Password:

Signifor

This page shows the latest Signifor news and features for those working in and with pharma, biotech and healthcare.

Novartis' acromegaly therapy cleared by FDA

Novartis' acromegaly therapy cleared by FDA

In trials, Signifor LAR showed superior efficacy to older somatostatin analogues, as measured by higher rates of biochemical control of GH and IGF-1 levels. ... Signifor LAR needs to be given just once a month, allowing it to compete head-to-head with

Latest news

  • Novartis gets EU nod for rare disease drug Signifor Novartis gets EU nod for rare disease drug Signifor

    This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.". ... Signifor LAR has been submitted worldwide for the treatment of acromegaly, with an application filed in the US earlier this year, said

  • Novartis plans filings for acromegaly candidate Novartis plans filings for acromegaly candidate

    Could add to Signifor’s indications. A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... The shorter-acting, subcutaneous form of Signifor was approved in 2012

  • Novartis cancer chief Hoppenot leaves for top job at Incyte Novartis cancer chief Hoppenot leaves for top job at Incyte

    During his time at the helm of Novartis' cancer division Hoppenot presided over the launch of two new cancer therapies, Jakavi for myelofibrosis in 2011 and Signifor (pasireotide) for Cushing's

More from news
Approximately 3 fully matching, plus 1 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics